EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Engineering a dual vaccine against COVID-19 and tuberculosis

Carlyn Monèt Guthrie, Xuejuan Tan, Amber Cherry Meeker, Ashton Elisabeth Self, Lin Liu, Yong Cheng

Frontiers in Cellular and Infection Microbiology · 2023

DOI: 10.3389/fcimb.2023.1273019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2023. Verfasst von Carlyn Monèt Guthrie und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Oklahoma State University, Stillwater, OK, United States. Hauptthemen laut MEDLINE: COVID-19, Tuberculosis, Communicable Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COVID-19 pandemic, caused by SARS-CoV-2 virus, has been one of the top public health threats across the world over the past three years. Mycobacterium bovis BCG is currently the only licensed vaccine for tuberculosis, one of the deadliest infectious diseases in the world, that is caused by Mycobacterium tuberculosis . In the past decades, recombinant M.bovis BCG has been studied as a novel vaccine vector for other infectious diseases in humans besides tuberculosis, such as viral infections. In the current study, we generated a recombinant M. bovis BCG strain AspikeRBD that expresses a fusion protein consisting of M. tb Ag85A protein and the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein using synthetic biology technique. Our results show that the recombinant M. bovis BCG strain successfully expressed this fusion protein. Interestingly, the recombinant M. bovis BCG strain AspikeRBD significantly induced SARS-CoV-2 spike-specific T cell activation and IgG production in mice when compared to the parental M.bovis BCG strain, and was more potent than the recombinant M.bovis BCG strain expressing SARS-CoV-2 spike RBD alone. As expected, the recombinant M. bovis BCG strain AspikeRBD activated an increased number of M. tb Ag85A-specific IFNγ-releasing T cells and enhanced IgG production in mice when compared to the parental M.bovis BCG strain or the BCG strain expressing SARS-CoV-2 spike RBD alone. Taken together, our results indicate a potential application of the recombinant M. bovis BCG strain AspikeRBD as a novel dual vaccine against SARS-CoV-2 and M. tb in humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19TuberculosisCommunicable DiseasesHumansAnimalsMiceCOVID-19 VaccinesBCG VaccinePandemicsAntigens, BacterialVaccines, SyntheticSARS-CoV-2Recombinant ProteinsImmunoglobulin GSpike Glycoprotein, Coronavirus

Stichwörter der Autor:innen

COVID-19Mycobacterium bovis BCGdual vaccinemicetuberculosis

Substanzen

COVID-19 VaccinesBCG VaccineAntigens, BacterialVaccines, SyntheticRecombinant ProteinsImmunoglobulin Gspike protein, SARS-CoV-2Spike Glycoprotein, Coronavirus

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, Oklahoma State University, Stillwater, OK, United States.
  • Oklahoma Center for Respiratory and Infectious Diseases, Oklahoma State University, Stillwater, OK, United States.
  • Department of Physiological Sciences, Oklahoma State University, Stillwater, OK, United States.

Förderung

  • NIGMS NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Guthrie, C. M., Tan, X., Meeker, A. C., Self, A. E., Liu, L., & Cheng, Y. (2023). Engineering a dual vaccine against COVID-19 and tuberculosis. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2023.1273019

Vancouver

Guthrie CM, Tan X, Meeker AC, Self AE, Liu L, Cheng Y. Engineering a dual vaccine against COVID-19 and tuberculosis. Frontiers in Cellular and Infection Microbiology. 2023. doi:10.3389/fcimb.2023.1273019

BibTeX
@article{Guthrie2023,
  author = {Guthrie, Carlyn Monèt and Tan, Xuejuan and Meeker, Amber Cherry and Self, Ashton Elisabeth and Liu, Lin and Cheng, Yong},
  title = {Engineering a dual vaccine against COVID-19 and tuberculosis},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2023},
  doi = {10.3389/fcimb.2023.1273019}
}
Kostenlos starten →